eCite Digital Repository

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis

Citation

Singh, A and Hussain, S and Antony, B, Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis, Diabetes & Metabolic Syndrome, 15, (3) pp. 813-822. ISSN 1871-4021 (2021) [Refereed Article]


Preview
PDF
Pending copyright assessment - Request a copy
916Kb
  

DOI: doi:10.1016/j.dsx.2021.03.019

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable population that may be susceptible to more severe COVID-19. Moreover, not only the underlying NAFLD may influence the progression of COVID-19, but the COVID-19 may affect the clinical course of NAFLD as well. However, comprehensive evidence on clinical outcomes in patients with NAFLD is not well characterized.

Objectives: To systematically review and meta-analysis the evidence on clinical outcomes in NAFLD patients with COVID-19.

Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through November 2020. Epidemiological studies assessing the clinical outcomes in COVID-19 patients with NAFLD were included. Newcastle-Ottawa Scale (NOS) was used to assess study quality. Generic inverse variance method using RevMan was used to determine the pooled estimates using the random-effects model.

Results: Fourteen studies consisting of 1851 NAFLD patients, were included. Significant heterogeneity was observed among the studies, and studies were of moderate to high quality [mean, (range):8 (6, 8)]. For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI:2.24-3.02; p < 0.001) (studies,n:8), aOR for admission to ICU due to COVID-19 was 1.66 (95%CI:1.26-2.20; p < 0.001) (studies,n:2), and aOR for mortality for was 1.01 (95%CI:0.65-1.58; p = 0.96) (studies,n:2).

Conclusions: An increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to conclusively elucidate the impact of NAFLD in patients with COVID-19.

Item Details

Item Type:Refereed Article
Keywords:NAFLD,COVID-19, mortality, severity, systematic review
Research Division:Health Sciences
Research Group:Epidemiology
Research Field:Major global burdens of disease
Objective Division:Health
Objective Group:Public health (excl. specific population health)
Objective Field:Overweight and obesity
UTAS Author:Singh, A (Mr Ambrish Singh)
UTAS Author:Antony, B (Dr Benny Eathakkattu Antony)
ID Code:144942
Year Published:2021
Web of Science® Times Cited:2
Deposited By:Menzies Institute for Medical Research
Deposited On:2021-06-22
Last Modified:2021-07-29
Downloads:0

Repository Staff Only: item control page